EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

RANKL is a mediator of bone resorption in idiopathic hypercalciuria



RANKL is a mediator of bone resorption in idiopathic hypercalciuria



Clinical Journal of the American Society of Nephrology 3(5): 1446-1452



This study aimed to determine the expression of osteoprotegerin, receptor activator of nuclear factor kappaB ligand, interleukin-1alpha, transforming growth factor-beta, and basic fibroblast growth factor in stone-forming patients with idiopathic hypercalciuria. Immunohistochemical analysis was performed in undecalcified bone samples previously obtained from 36 transiliac bone biopsies of patients who had idiopathic hypercalciuria and whose histomorphometry had shown lower bone volume, increased bone resorption, and prolonged mineralization lag time. Bone expression of receptor activator of nuclear factor kappaB ligand and osteoprotegerin was significantly higher in patients with idiopathic hypercalciuria versus control subjects. Transforming growth factor-beta immunostaining was lower in patients with idiopathic hypercalciuria than in control subjects and correlated directly with mineralization surface. Interleukin-1alpha and basic fibroblast growth factor staining did not differ between groups. Receptor activator of nuclear factor kappaB ligand bone expression was significantly higher in patients who had idiopathic hypercalciuria and exhibited higher versus normal bone resorption. A higher expression of receptor activator of nuclear factor kappaB ligand in bone tissue suggests that increased bone resorption in patients with idiopathic hypercalciuria is mediated by receptor activator of nuclear factor kappaB ligand. Osteoprotegerin bone expression might have been secondarily increased in an attempt to counteract the actions of receptor activator of nuclear factor kappaB ligand. The low bone expression of transforming growth factor-beta could contribute to the delayed mineralization found in such patients.

(PDF emailed within 0-6 h: $19.90)

Accession: 055333183

Download citation: RISBibTeXText

PMID: 18480302

DOI: 10.2215/CJN.00240108



Related references

Increased bone resorption in children with idiopathic hypercalciuria. Pediatric Nephrology 12(7): C108, Sept, 1998

Bone resorption in dogs with calcium oxalate urolithiasis and idiopathic hypercalciuria. Research in Veterinary Science 123: 129-134, 2019

Early predictors of increased bone resorption in juvenile idiopathic arthritis OPG/RANKL ratio, as a key regulator of bone metabolism. The Egyptian Rheumatologist 33(4): 0-223, 2011

Osteocyte-derived RANKL is a critical mediator of the increased bone resorption caused by dietary calcium deficiency. Bone 66: 146-154, 2015

A longitudinal study of total and regional bone mineral content and biochemical markers of bone resorption in patients with idiopathic hypercalciuria on thiazide treatment. Mineral and Electrolyte Metabolism 19(6): 337-342, 1993

Idiopathic hypercalciuria and osteoporosis--distinct clinical manifestations of increased cytokine-induced bone resorption?. Journal of Clinical Endocrinology and Metabolism 82(1): 29-31, 1997

Anti calciuric diuretics and potassium bicarbonate reduce bone resorption in patients with idiopathic hypercalciuria ih. Clinical Research 39(2): 469A, 1991

Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. Immunological Reviews 208: 30-49, 2005

Discovery of osteoclast differentiation factor, RANKL Inhibition of bone resorption by blocking RANKL-RANK signaling. Japanese Journal of Pharmacology 88(Supplement 1): 17P, 2002

Bone mineral loss in idiopathic hypercalciuria Role of cytokines and type of hypercalciuria. Journal of the American Society of Nephrology 3(3): 670, 1992

Stimulation of bone resorption in cultured mouse calvaria by Lys-bradykinin (kallidin), a potential mediator of bone resorption linking anaphylaxis processes to rarefying osteitis. Bone and Mineral 1(4): 267-277, 1986

Stimulation of bone resorption in cultured mouse calvaria by lysine bradykinin kallidin a potential mediator of bone resorption linking anaphylaxis processes to rarefying osteitis. Bone & Mineral 1(4): 267-278, 1986

Idiopathic external root resorption associated to hypercalciuria. Medicina Oral 7(3): 192-199, 2002

Resolvin E1 Inhibits Osteoclastogenesis and Bone Resorption by Suppressing IL-17-induced RANKL Expression in Osteoblasts and RANKL-induced Osteoclast Differentiation. Yonago Acta Medica 61(1): 8-18, 2018

Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. Journal of Bone and Mineral Research 24(2): 182-195, 2008